Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives

Breast Carcinoma Clinical Trial

Official title: Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives

Status Active, not recruiting

Clinical Trial Summary

This trial collects information about factors that affect communication of genetic test results, decision-making, and access to genetic testing in women with hereditary gynecological cancers. Studying individuals who are positive for a genetic mutation and immediate biological family members (including a parent, full-sibling, or child) may help identify cancer genes and other persons at risk.

Clinical Trial Description

PRIMARY OBJECTIVES:

I. Identify and explore factors influencing the communication of genetic testing results from probands (patients with confirmed hereditary cancer predisposition syndrome) to their first-degree relatives. (Step 1) II. Identify and explore factors influencing decision making and pursuit of cascade testing among first-degree relatives of probands. (Step 1) III. Estimate the uptake of cascade testing by first-degree relatives of probands at a safety-net hospital and the uptake of cascade testing by first-degree relatives of probands at a comprehensive cancer center. (Step 2) IV. Estimate the frequency of reported factors that influence communication, decision-making, and pursuit of cascade testing among probands and their first-degree family members at a safety-net hospital and at a comprehensive cancer center. (Step 2) V. Explore similarities and differences in cascade genetic testing rates and reported barriers to cascade genetic testing of first-degree relatives at probands from a safety-net hospital and a comprehensive cancer center. (Step 2)

OUTLINE:

STEP I: Patients and first degree relatives participate in semi-structure, in-depth interviews about genetic testing over 45-60 minutes.

STEP II: Patients and first degree relatives complete survey questionnaires over 20 minutes. ;

Related Conditions & MeSH terms

• Breast Carcinoma
• Breast Neoplasms
• Carcinoma
• Deleterious CDH1 Gene Mutation
• Deleterious DICER1 Gene Mutation
• Deleterious SMARCA4 Gene Mutation
• Deleterious STK11 Gene Mutation
• Endometrial Carcinoma
• Endometrial Neoplasms
• Fallopian Tube Carcinoma
• Ovarian Carcinoma
• Primary Peritoneal Carcinoma

• NCT number: NCT04257045
• Study type: Observational
• Source: M.D. Anderson Cancer Center
• Status: Active, not recruiting
• Start date: August 21, 2019
• Completion date: April 30, 2024